An observational study in Pancreatic Cancer and Pancreas Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by Memorial Sloan Kettering Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Pancreatic Neoplasms by Memorial Sloan Kettering Cancer Center — 8 open to participants now, 20 under way, none of them phase 3. Pancreatic Neoplasms · Memorial Sloan Kettering Cancer Center.
Among the 50 studies in Pancreatic Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 8th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2026, is one of 12 observational ones, reaches primary completion later than 17 of the 19 other live ones, and was the 48th registered.
3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →8 of the 50 studies in Pancreatic Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 2 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 12 · Phase 3 5
First in 1997; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 79 is below the median of 200 across 743 observational studies indexed under Pancreatic Neoplasms.
Median enrollment 30 across the 33 interventional studies, 100 across the 12 observational. Of the 28 that completed or were terminated, 9 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
14 of the studies in Pancreatic Neoplasms by Memorial Sloan Kettering Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05642962Memorial Sloan Kettering Cancer CenterPancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) | 2026-11-30 |
| NCT00582647Memorial Sloan Kettering Cancer CenterCollection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract | 2026-12 |
| NCT06168812Memorial Sloan Kettering Cancer CenterA Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer | 2026-12-05 |
| NCT03033927Memorial Sloan Kettering Cancer CenterPredicting Effective Therapy in Pancreatic Cancer | 2027-01-24 |
| NCT02393703Memorial Sloan Kettering Cancer CenterInterrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer | 2027-03 |
Add all 14 to your calendar (.ics) → With an account.
Among the 50 studies in Pancreatic Neoplasms by Memorial Sloan Kettering Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to develop a dedicated MRI scan of the pancreas (MRP) to better detect pancreatic cancer in people who are at a high risk for pancreatic cancer.
Investigators will conduct this pilot study in high-risk individuals enrolled in the Memorial Sloan Kettering Pancreatic Tumor Registry
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For this pilot MRP study, we will additionally apply the following Criteria:
We will recruit surveillance participants who had at least one prior MRCP in the last 3 years. They must also undergo a same-day EUS procedure as part of their surveillance. Nearly all active cohort participants have had at least one recent MRCP and, on average, our Registry gastroenterologist Dr. Rolston performs EUS in \~260 surveillance participants per year. Accordingly, it is highly feasible to recruit more than 79 participants in the grant period, and recruitment is constrained by budget.
Documentation of Disease
o No pathologic confirmation of disease is necessary
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be high-risk individuals enrolled in the Memorial Sloan Kettering Pancreatic Tumor Registry
Diagnostic Test: MRI · Diagnostic Test: Endoscopic ultrasound
Participants will undergo a single MRI of the abdomen without contrast
Also known as: Magnetic Resonance CholangioPancreatography, MRP
EUS will be scheduled the same day or within 2 weeks prior to MRP
Also known as: EUS
Compare image quality of novel high-resolution magnetic resonance pancreas (MRP) to conventional MRCP
Develop and pilot a focused high-resolution magnetic resonance pancreas (MRP) exam to help facilitate early pancreatic cancer detection in high-risk individuals. Image quality for T1, T2, and DWI sequences performed on the novel MRP exam will be compared to conventional MRCP performed in the same participants.
Time frame: Up to 3 years
Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Started May 2026 (actual). Primary completion is estimated for May 2028, 24 months after the start.
Of 318 non-industry observational studies under Pancreatic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 182. This study's planned 24 months is below that.
Counting every sponsor, half of 352 studies reached it within 60 months; a quarter within 34 and three quarters within 182.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →